Sequenta, Inc. Issued Third U.S. Patent, Augmenting Its Strong Intellectual Property Portfolio

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta Inc. today announced the issuance of its third U.S. patent, “Monitoring Health and Disease Status Using Clonotype Profiles” (Patent No. 8,628,927), which covers minimal residual disease (MRD) monitoring under conditions of clonal evolution, a common source of false negative results with existing MRD detection technology. The methods covered by this patent will provide exclusive protection for Sequenta’s ClonoSIGHT™ test in a range of cancers where clonal evolution commonly occurs, such as leukemias and non-Hodgkin’s lymphoma. Sequenta has now been issued a total of nine patents worldwide and has pending allowances in an additional three U.S. applications.

Help employers find you! Check out all the jobs and post your resume.